What: Clinical Proteomic Technology Assessment for Cancer teams
The National Cancer Institute (NCI), part of the National Institutes of Health, will host a telebriefing to announce five Clinical Proteomic Technology Assessment for Cancer (CPTAC) teams. A major component of its $104 million, five-year Clinical Proteomic Technologies Initiative, the CPTAC awards total $35.5 million over five years.
The CPTAC teams will bring complementary expertise to assess the full spectrum of measurement technologies for proteins and peptides relevant to clinical cancer research and practice. The network's collaborative efforts will guide and provide resources to the broader cancer research community, enabling researchers conducting cancer-related protein research at different laboratories to use proteomic technologies and methodologies to directly compare their work. Standardized technologies and methodologies are critically needed in current cancer proteomic research.
Who: Anna D. Barker, Ph.D., NCI deputy director, advanced technologies and strategic partnerships
Lee Hartwell, Ph.D., president and director, Fred Hutchinson Cancer Research Center
Steven A. Carr, Ph.D., Broad Institute of MIT and Harvard
Joe Gray, Ph.D., University of California, San Francisco/Lawrence Berkeley National Laboratory
Daniel C. Liebler, Ph.D., Vanderbilt University School of Medicine
Fred E. Regnier, Ph.D., Purdue University
Paul Tempst, Ph.D., Memorial Sloan-Kettering Cancer Center
When: Wednesday, September 27, 2006 1:00 p.m. - 2:00 p.m. EDT
The media briefing is available to reporters via a toll-free conference line at 1-866-755-5928 (teleconference number: 7211683) in the United States and Canada.
'"/>
Contact: NCI Media Relations Branch
ncipressofficers@mail.nih.gov
301-496-6641
NIH/National Cancer Institute
27-Sep-2006